Asset Details
Do you wish to reserve the book?
Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis
Do you wish to request the book?
Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis
2024
Overview
Purpose
To compare disease-free survival (DFS), overall survival (OS), and adverse events (AEs) among muscle-invasive urothelial carcinoma (MIUC) patients receiving adjuvant immune checkpoint inhibitors (ICIs) versus placebo/observation following radical surgery.
Methods
This was a systematic review/meta-analysis of all published phase 3 randomized controlled trials. MEDLINE, EMBASE, and Cochrane were searched from inception until April 4, 2024. Pooled hazard ratios (HR) and relative risks (RR), plus confidence intervals (CI), were generated using frequentist random-effects modeling.
Results
Three trials were identified: IMvigor010, CheckMate 274, and AMBASSADOR. In the overall cohort, adjuvant ICIs significantly improved DFS by 23% (HR = 0.77, 95% CI = 0.65–0.90). No DFS benefit was observed in patients with upper tract disease (HR = 1.19, 95% CI = 0.86–1.64). The highest magnitude of DFS benefit was observed among patients who had received prior neoadjuvant chemotherapy (HR = 0.69) and pathologic node-positive disease (HR = 0.75). A similar DFS benefit was observed irrespective of tumor PD-L1 status. Pooled OS demonstrated a 13% non-significant benefit (HR = 0.87, 95% CI = 0.75–1.01). Grade ≥ 3 immune-mediated AEs occurred in 8.6% and 2.1% of ICI and placebo/observation patients, respectively (RR = 4.35, 95% CI = 1.02–18.5). AEs leading to treatment discontinuation occurred in 14.3% and 0.9% of patients, respectively.
Conclusion
Adjuvant ICIs confer a DFS benefit following radical surgery for MIUC, particularly among node-positive patients and those who received prior neoadjuvant chemotherapy. The lack of benefit for upper tract disease suggests that alternate adjuvant approaches, including chemotherapy, should be considered for these patients. Tumor PD-L1 status is not a predictive biomarker, highlighting the need for biomarkers in this setting.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Carcinoma, Transitional Cell - drug therapy
/ Carcinoma, Transitional Cell - pathology
/ Carcinoma, Transitional Cell - surgery
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - therapeutic use
/ Medicine
/ Oncology
/ Patients
/ Placebos
/ Randomized Controlled Trials as Topic
/ Surgery
/ Survival
/ Tumors
/ Urinary Bladder Neoplasms - drug therapy
/ Urinary Bladder Neoplasms - pathology
/ Urinary Bladder Neoplasms - surgery
/ Urology
